GlassScriptPhysician profile
Rupal R Desai
NPI 1376634626
$3,195.92
in general payments reported to CMS, 2019-2025
33 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $76.92 · 2022: $227 · 2023: $521 · 2024: $787 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $391.88 | 2019-2025 | |
| Astellas Pharma US INC | $354.77 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.27 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $292.70 | 2019-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $292.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $259.65 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $147.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $145.61 | 2019-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $121.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $107.94 | 2019-2024 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $73.32 | 2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $69.65 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $62.31 | 2019-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $57.86 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.52 | 2019-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.93 | 2019 | |
| Acella Pharmaceuticals, LLC | $42.36 | 2024-2025 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $41.04 | 2025 | |
| Sumitomo Pharma America, INC. | $39.70 | 2023-2025 | Gemtesa |
| Bausch Health US, LLC | $39.66 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.72 | 2024-2025 | Caplyta |
| Sanofi Pasteur INC. | $27.46 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.91 | 2019-2020 | |
| Aerin Medical INC. | $22.97 | 2025 | |
| Itamar Medical INC | $19.30 | 2023 | Watchpatone |
| Amneal Pharmaceuticals LLC | $18.32 | 2024 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $17.76 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.69 | 2025 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $15.37 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.00 | 2019 | |
| Allergan, INC. | $13.62 | 2020 | |
| Medtronic, INC. | $13.59 | 2025 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.